🔗 Share this article

Ex-government leader Rishi Sunak has reinforced his campaign for a specialized screening programme for prostate gland cancer.

During a recently conducted discussion, he declared being "certain of the immediate need" of implementing such a initiative that would be cost-effective, feasible and "preserve numerous lives".

His remarks come as the National Screening Advisory Body reviews its ruling from the previous five-year period against recommending routine screening.

News sources indicate the body may maintain its present viewpoint.

Athlete Adds Voice to Movement

Gold medal cyclist Sir Chris Hoy, who has late-stage prostate cancer, supports younger men to be checked.

He suggests reducing the age threshold for obtaining a prostate-specific antigen blood test.

Currently, it is not routinely offered to men without symptoms who are below fifty.

The PSA test remains disputed nevertheless. Levels can elevate for reasons apart from cancer, such as inflammation, resulting in false positives.

Skeptics contend this can lead to unwarranted procedures and side effects.

Focused Screening Initiative

The proposed testing initiative would concentrate on individuals in the 45-69 age bracket with a hereditary background of prostate gland cancer and men of African descent, who encounter double the risk.

This group includes around 1.3 million individuals men in the UK.

Research projections indicate the system would cost £25m annually - or about £18 per person per patient - akin to bowel and breast cancer screening.

The assumption envisions 20% of qualified individuals would be contacted each year, with a 72% response rate.

Medical testing (imaging and tissue samples) would need to increase by almost a quarter, with only a moderate expansion in medical workforce, based on the report.

Clinical Professionals Reaction

Several healthcare professionals are uncertain about the value of testing.

They contend there is still a risk that individuals will be medically managed for the disease when it is not strictly necessary and will then have to endure complications such as incontinence and sexual performance issues.

One prominent urological professional stated that "The issue is we can often find conditions that may not require to be managed and we potentially create harm...and my apprehension at the moment is that negative to positive equation isn't quite right."

Patient Perspectives

Personal stories are also shaping the conversation.

One instance concerns a 66-year-old who, after asking for a prostate screening, was identified with the disease at the time of 59 and was advised it had metastasized to his pelvis.

He has since received chemical therapy, radiation treatment and hormonal therapy but remains incurable.

The patient supports screening for those who are genetically predisposed.

"That is essential to me because of my boys – they are 38 and 40 – I want them tested as promptly. If I had been examined at 50 I am certain I would not be in the circumstances I am today," he said.

Future Actions

The Medical Screening Authority will have to weigh up the information and viewpoints.

Although the new report indicates the consequences for staffing and accessibility of a screening programme would be achievable, others have maintained that it would take imaging resources away from individuals being treated for different health issues.

The ongoing debate underscores the complex trade-off between early detection and likely unnecessary management in prostate cancer treatment.